Seelos Therapeutics (NASDAQ:SEEL) vs. Zoetis (NYSE:ZTS) Head to Head Comparison

Seelos Therapeutics (NASDAQ:SEEL) and Zoetis (NYSE:ZTS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Seelos Therapeutics and Zoetis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seelos Therapeutics	0	0	0	0	N/A
Zoetis	0	0	9	1	3.10

Zoetis has a consensus target price of $221.44, indicating a potential upside of 17.17%. Given Zoetis’ higher probable upside, analysts clearly believe Zoetis is more favorable than Seelos Therapeutics.

Earnings and Valuation

This table compares Seelos Therapeutics and Zoetis”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seelos Therapeutics	$2.20 million	1.14	-$37.88 million	N/A	N/A
Zoetis	$8.92 billion	9.67	$2.34 billion	$5.19	36.41

Zoetis has higher revenue and earnings than Seelos Therapeutics.

Institutional and Insider Ownership

23.4% of Seelos Therapeutics shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 5.4% of Seelos Therapeutics shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Seelos Therapeutics and Zoetis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seelos Therapeutics	203.13%	N/A	-431.47%
Zoetis	26.29%	50.67%	17.88%

Risk and Volatility

Seelos Therapeutics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Summary

Zoetis beats Seelos Therapeutics on 9 of the 12 factors compared between the two stocks.

About Seelos Therapeutics

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.